Efficacy and Tolerability of Pyrazolo[1,5-
Journal
ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073
Informations de publication
Date de publication:
09 Apr 2020
09 Apr 2020
Historique:
received:
10
01
2020
accepted:
12
02
2020
entrez:
16
4
2020
pubmed:
16
4
2020
medline:
16
4
2020
Statut:
epublish
Résumé
RET (REarranged during Transfection) kinase gain-of-function aberrancies have been identified as potential oncogenic drivers in lung adenocarcinoma, along with several other cancer types, prompting the discovery and assessment of selective inhibitors. Internal mining and analysis of relevant kinase data informed the decision to investigate a pyrazolo[1,5-
Identifiants
pubmed: 32292564
doi: 10.1021/acsmedchemlett.0c00015
pmc: PMC7153282
doi:
Types de publication
Journal Article
Langues
eng
Pagination
558-565Subventions
Organisme : NIGMS NIH HHS
ID : P30 GM124169
Pays : United States
Informations de copyright
Copyright © 2020 American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Cancers (Basel). 2019 May 03;11(5):
pubmed: 31058838
Lung Cancer (Auckl). 2019 Mar 20;10:27-36
pubmed: 30962732
J Clin Oncol. 2016 May 20;34(15):e141-4
pubmed: 25366691
Cancer Treat Rev. 2019 Dec;81:101911
pubmed: 31715421
CA Cancer J Clin. 2013 Jul-Aug;63(4):249-79
pubmed: 23716430
Drug Saf. 2013 Jun;36(6):413-26
pubmed: 23620170
Cancer Discov. 2018 Jul;8(7):836-849
pubmed: 29657135
Dev Biol. 2008 Jan 1;313(1):279-92
pubmed: 18031721
Lung Cancer. 2015 Jul;89(1):76-9
pubmed: 25982012
Nat Rev Cancer. 2013 Nov;13(11):772-87
pubmed: 24132104
Onco Targets Ther. 2013;6:1-7
pubmed: 23319867
J Med Chem. 2007 Nov 15;50(23):5773-9
pubmed: 17948979
ACS Med Chem Lett. 2018 May 24;9(7):623-628
pubmed: 30034590
J Med Chem. 2015 May 14;58(9):3672-81
pubmed: 25625428
J Clin Endocrinol Metab. 2013 May;98(5):E811-9
pubmed: 23526464
Expert Opin Ther Pat. 2017 Jan;27(1):91-99
pubmed: 27646564
Eur J Med Chem. 2016 Apr 13;112:20-32
pubmed: 26874741
J Thorac Oncol. 2016 Nov;11(11):2027-2032
pubmed: 27544060
Pharmacol Res. 2018 Feb;128:1-17
pubmed: 29284153
Ann Oncol. 2017 Feb 1;28(2):292-297
pubmed: 27803005
Curr Opin Oncol. 2007 Jan;19(1):55-60
pubmed: 17133113
J Chem Inf Model. 2007 May-Jun;47(3):1196-205
pubmed: 17428028
Cell. 1985 Sep;42(2):581-8
pubmed: 2992805
Front Physiol. 2019 Jan 07;9:1873
pubmed: 30666215
Onco Targets Ther. 2019 Jan 18;12:635-645
pubmed: 30705592